SCHEMBL6445774

SCHEMBL6445774

COc1ccc(C(=O)Nc2nnc(-c3cc(Cl)cc(Cl)c3O)s2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 2/20 0.54
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
RXFP1 Q9HBX9 2/20 0.52
MAPT P10636 7/20 0.52
TP53 P04637 3/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
ALOX15 P16050 1/20 0.50
CYP2C19 P33261 1/20 0.50
THRB P10828 2/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.47
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6448596 0.93 SMN1; SMN2 (0.52) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6447124 0.91 PTGER3 (0.52) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6446057 0.88 ALDH1A1 (0.58) PTGER3KMT2AMEN1MAPTLMNA
SCHEMBL6445716 0.87 GLB1 (0.49) PTGER3KMT2AMEN1MAPTLMNA
SCHEMBL6448931 0.86 PTGER3 (0.46) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6448556 0.85 KDM4E (0.62) PTGER3KMT2AMEN1MAPTTP53
SCHEMBL6445474 0.84 KDM4E (0.53) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6448951 0.84 AKR1C4 (0.48) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6446020 0.84 KMT2A (0.48) PTGER3KMT2AMEN1RXFP1MAPT
SCHEMBL6448551 0.84 KDM4E (0.48) PTGER3KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 PTGER3 332/4885KMT2A 3566/4885MEN1 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.